Latest Can-Fite BioPharma News & Updates

See the latest news and media coverage for Can-Fite. We track all announcements, press releases, and industry mentions in real time, all in one place.

Can-Fite BioPharma (Can-Fite)

Biopharmaceutical company developing oral drugs for oncology and inflammatory diseases

canfite.com

Last updated Today

Latest news about Can-Fite BioPharma (Can-Fite)

In short: Can-Fite advanced its clinical pipeline, reporting positive pancreatic cancer data and securing key patent allowances for its lead drug candidates.

Company announcements

June 2 Can-Fite

Can-Fite highlights Namodenoson's RAS inhibition in pancreatic cancer

The Phase 2a study showed prolonged disease control in patients, including one patient on therapy for 16 months.

May 13 Can-Fite

Can-Fite advances Namodenoson into Phase 2b trial

The study will evaluate Namodenoson with immunotherapy in advanced pancreatic cancer, assessing progression-free survival, overall survival, and disease stabilization. Study design to be discussed at BIO convention.

March 30 Can-Fite

Can-Fite's partner Vetbiolix completes Phase 2 osteoarthritis study enrollment

Top-line results are expected in Q3 2026. The deal is worth up to $325M.

March 26 Can-Fite

Can-Fite reports 2025 financial results and clinical progress

Highlights include positive Phase 2a pancreatic cancer data and a liver cancer patient with 9-year cancer-free survival.

Media coverage

June 2 Yahoo Finance

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism

Growing momentum for RAS inhibition at ASCO highlights Namodenoson’s RAS pathway inhibition and encouraging data in pancreatic cancer Ramat Gan, Israel, June 02, 2026 (GLOBE...

April 30 Markets Insider

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of...

March 1 Yahoo Finance

CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced...

23 December 2025 MarketWatch

Can-Fite BioPharma Initiating a 1-for-3,000 Reverse Share Split; ADSs Tumble

Can-Fite BioPharma's American depositary shares slid after its board of directors approved a 1-for-3,000 reverse share split. The ADSs were down 29% to 17 cents...

Never miss news about Can-Fite

Track Can-Fite and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.